DCR LLY11
Alternative Names: DCR-LLY11Latest Information Update: 01 Feb 2022
Price :
$50 *
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Dicerna Pharmaceuticals; Eli Lilly and Company
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 28 Jan 2022 Dicerna Pharmaceuticals enters into a licensing agreement with Eliy Lily for the development of RNAi therapies (Dicerna Pharmaceutical pipeline; January 2022)
- 20 Jan 2022 Dicerna Pharmaceuticals was acquired by Novo Nordisk .
- 20 Jan 2022 Preclinical trials in Neurodegenerative disorders in USA (Parenteral) (Dicerna Pharmaceuticals pipeline, January 2022)